. [eighty two] to assess the efficacy, safety and tolerability of Cannabidiol as an adjunct therapy in conjunction with anti-epileptic medicines on the patients struggling from tuberous sclerosis advanced whose most frequent neurological symptom is epilepsy. On this medical demo research, just a